L'intérêt à découvert pour Perspective Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Perspective Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Perspective Therapeutics (AMEX:CATX) Stock, Rapport sur les intérêts à découvert

Perspective Therapeutics

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

News

Boeing CEO Says Planning To Reduce Size Of Total Workforce By Roughly 10%, Over Coming Months; "Our Business Is In A Difficult Position"; On 777x Program, Challenges Faced In Development, Flight Test Pause, Ongoing Work Stoppage, To Delay Program Timeline; On 777x Program, Now Expect First Delivery In 2026; Plan To Build & Deliver Remaining 767 Freighters Ordered & Then Conclude Production Of Commercial Program In 2027

Guidance

Boeing Sees Prelim. Q3 Revenue $17.8B Vs $18.432B Est.

High-rolling investors have positioned themselves bullish on Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ROKU often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Roku. This is not a typical pattern.
The sentiment among these major traders is split, with 81% bullish and 9% bearish. Among all the options we identified, there was one put, amounting to $42,750, and 10 calls, totaling $426,979.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $110.0 for Roku over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Roku's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Roku's whale trades within a strike price range from $50.0 to $110.0 in the last 30 days. 
<h3>Roku Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728678730_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$2.32</td>
<td>$2.06</td>
<td>$2.31</td>
<td>$80.00</td>
<td>$70.2K</td>
<td>513</td>
<td style="text-align: right;">978</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$110.00</td>
<td>$69.3K</td>
<td>6</td>
<td style="text-align: right;">199</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$31.35</td>
<td>$31.0</td>
<td>$31.2</td>
<td>$50.00</td>
<td>$62.4K</td>
<td>433</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$2.28</td>
<td>$2.2</td>
<td>$2.21</td>
<td>$80.00</td>
<td>$43.5K</td>
<td>513</td>
<td style="text-align: right;">675</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.45</td>
<td>$9.3</td>
<td>$9.4</td>
<td>$75.00</td>
<td>$43.2K</td>
<td>1.0K</td>
<td style="text-align: right;">83</td>
</tr>
</tbody>
</table>

<h3>About Roku</h3>
Roku enables consumers to stream television programming. It has more than 80 million streaming households and provided well over 100 billion streaming hours in 2023. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.
<h3>Roku's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,206,468, the price of ROKU is up by 1.29%, reaching $78.37.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>What The Experts Say On Roku</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $92.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Roku, targeting a price of $77. 
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Roku with a target price of $90. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Roku, targeting a price of $92. 
&#x2A; An analyst from Benchmark downgraded its action to Buy with a price target of $105. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $100.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Roku options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

ROKU

What the Options Market Tells Us About Roku

<h3>Gainers</h3>
<ul>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) stock moved upwards by 20.9% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $9.4 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares increased by 4.35% to $0.17. The company's market cap stands at $23.5 million. </li>
<li>Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) stock rose 2.55% to $0.16. The company's market cap stands at $15.3 million. </li>
<li>Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) stock moved upwards by 2.07% to $9.35. The market value of their outstanding shares is at $155.4 million. </li>
<li>Exela Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELA#NASDAQ">XELA</a>) stock rose 1.89% to $2.08. The market value of their outstanding shares is at $13.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares decreased by 6.3% to $0.64 during Friday's after-market session. The company's market cap stands at $16.3 million. </li>
<li>noco-noco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares decreased by 5.55% to $0.1. The company's market cap stands at $18.4 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock declined by 5.11% to $0.84. The market value of their outstanding shares is at $16.6 million. </li>
<li>Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) shares declined by 4.71% to $2.23. The market value of their outstanding shares is at $141.8 million. </li>
<li>SolarMax Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares decreased by 4.27% to $0.88. The market value of their outstanding shares is at $39.4 million. </li>
<li>Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares declined by 4.21% to $0.57. The company's market cap stands at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AQMS

CSLR

MNTS

NCNC

OPTT

SMXT

SPPL

ULBI

WATT

XELA

11 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares moved upwards by 12.6% to $4.2 during Friday's after-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Yunhong Green CTI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHGJ#NASDAQ">YHGJ</a>) stock increased by 9.82% to $0.82. The market value of their outstanding shares is at $21.3 million. </li>
<li>Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) stock rose 8.1% to $5.6. The company's market cap stands at $158.0 million. </li>
<li>Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) stock moved upwards by 4.85% to $2.16. The company's market cap stands at $18.5 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock moved upwards by 4.07% to $0.19. The company's market cap stands at $10.6 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock rose 3.64% to $0.81. The company's market cap stands at $2.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mynd.ai (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYND#AMEX">MYND</a>) stock decreased by 5.2% to $1.29 during Friday's after-market session. The company's market cap stands at $58.8 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 5.01% to $0.21. The market value of their outstanding shares is at $8.1 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares fell 4.65% to $0.5. The company's market cap stands at $4.8 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares declined by 4.35% to $0.17. </li>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares fell 3.36% to $0.77. The company's market cap stands at $3.5 million. </li>
<li>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares declined by 3.25% to $0.77. The market value of their outstanding shares is at $18.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTNT

DBGI

EDUC

FEBO

MYND

RIME

SBET

VLCN

WKHS

YHGJ

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

AKAN

ALLK

BLRX

CARA

DWTX

IMNM

NIVF

PTIX

TVGN

UNCY

12 Health Care Stocks Moving In Friday's After-Market Session

X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) (the "Company" or "XTKG"), a global provider of digital solutions and technology services spanning diverse industries, today announced that it has received an extension of 180 calendar days from the&nbsp;Listing Qualifications Department of The&nbsp;Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum&nbsp;$1.00&nbsp;bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Bid Price Requirement"). As a result of the extension, the Company has until April 7, 2025, to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company's ordinary shares&nbsp;must be at least US$1.00 for a minimum of 10 consecutive business days prior to April 7, 2025. Nasdaq would then provide a written confirmation of compliance and the matter will be closed.

XTKG

X3 Holdings Receives Extension Until April 7, 2025, To Regain Compliance With The Bid Price Requirement

<h3>Gainers</h3>
<ul>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) stock increased by 5.8% to $0.15 during Friday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock rose 4.03% to $1.29. The market value of their outstanding shares is at $11.5 million. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock increased by 2.81% to $0.18. The company's market cap stands at $2.4 million. </li>
<li>Akoustis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares rose 2.8% to $0.08. The market value of their outstanding shares is at $11.9 million. </li>
<li>Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) stock increased by 2.65% to $3.83. The market value of their outstanding shares is at $26.7 million. </li>
<li>Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) shares increased by 2.57% to $31.5. The company's market cap stands at $3.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) stock fell 5.9% to $5.53 during Friday's after-market session. The company's market cap stands at $84.4 million. </li>
<li>QXO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares fell 4.68% to $14.86. The company's market cap stands at $6.0 billion. </li>
<li>Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) shares decreased by 4.32% to $1.11. The market value of their outstanding shares is at $98.2 million. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) stock declined by 4.15% to $5.09. The market value of their outstanding shares is at $371.4 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock fell 3.93% to $0.24. The company's market cap stands at $4.4 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares decreased by 3.11% to $0.41. The company's market cap stands at $12.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIXI

AKTS

ATGL

BRZE

DTST

FOXO

LAES

LIDR

REKR

XTIA

12 Information Technology Stocks Moving In Friday's After-Market Session

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 5 years by 11.42% on an annualized basis producing an average annual return of 25.58%. Currently, Meta Platforms has a market capitalization of $1.49 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 5 years ago, it would be worth $3,218.85 today based on a price of $589.40 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728678620_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Meta Platforms Stock In The Last 5 Years

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 10 years by 6.69% on an annualized basis producing an average annual return of 18.71%. Currently, Amphenol has a market capitalization of $78.95 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 10 years ago, it would be worth $5,571.28 today based on a price of $65.56 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728678615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Amphenol Stock In The Last 10 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 48.15% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 25.56% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 19.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 14.83% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 9.04% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 7.07% at $2.05</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 5.55% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 5.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 5.11% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 4.58% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 4.37% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 4.29% at $1.42</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 4.03% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.74% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed up 3.46% at $124.85</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 32.43% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 27.71% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 26.77% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 20.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 13.96% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 9.09% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 9.09% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 7.83% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 6.22% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 5.72% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 4.97% at $0.21</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 4.53% at $0.54</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BBRRF

BMMJ

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNTMF

CXXIF

EAST

ELLXF

FFNTF

GRWG

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MGWFF

MRMD

OILFF

RMHB

RSSFF

SOLCF

TGIFF

UGRO

XXII

Marijuana Stock Movers For October 11, 2024

One week after the disclosure of the <a href="https://www.benzinga.com/news/24/10/41200026/chinese-hackers-breach-at-t-verizon-networks-in-major-wiretap-data-theft-putting-us-national-securit">hacking campaign targeting U.S. telecom companies</a>, members of Congress are still assessing the implications. The Chinese Salt Typhoon group is reportedly responsible for infiltrating AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), and Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), raising concerns that sensitive government data related to court-authorized wiretaps may have been compromised.
As The Wall Street Journal <a href="https://www.wsj.com/politics/national-security/u-s-officials-race-to-understand-severity-of-chinas-salt-typhoon-hacks-6e7c3951">reported</a>, congressional committees have sent letters to the chief executives of the three companies requesting detailed explanations about the intrusion and the steps taken to secure their systems.
Rep. Cathy McMorris Rodgers (R-WA), chairwoman of the House Energy and Commerce Committee, asked the companies to provide a full briefing by the end of next week.
&#8220;These types of breaches are increasing in frequency and severity,&#8221; the letter states. &#8220;The committee needs to understand better how this incident occurred and what steps your company is taking to prevent future service disruptions and secure your customers&#8217; data.&#8221;
Rep. John Moolenaar (R-MI) and Rep. Raja Krishnamoorthi (D-IL), on behalf of the House Select Committee on China, raised concerns that the breach could have severe national security implications.
&#8220;We face a cyber-adversary the likes of which we have never confronted before, and we must urgently enhance our nation's approach to cybersecurity,&#8221; they <a href="https://selectcommitteeontheccp.house.gov/sites/evo-subsites/selectcommitteeontheccp.house.gov/files/evo-media-document/10.10.24_Letter%20to%20Verizon%20ATT%20and%20Lumen.pdf">stated</a>.
The Chinese Embassy in Washington has denied any involvement in the attack. &#8220;China firmly opposes and combats cyberattacks in all forms,&#8221; a spokesperson said, rejecting claims that the Chinese government was behind the breach.
Meanwhile, Sen. Ron Wyden (D-OR), a member of the Senate Intelligence Committee and a leading advocate on cybersecurity issues, sent a letter to the Justice Department and the Federal Communications Commission (FCC).
The government shares much of the blame,&#8221; Wyden wrote, criticizing the longstanding inaction on vulnerabilities in wiretap systems required under the Communications Assistance for Law Enforcement Act (CALEA).
CALEA, which passed in 1994, mandates that telecom providers maintain systems that allow law enforcement to intercept communications. The law was expanded in 2005 to include broadband and internet-based services, leaving private companies responsible for ensuring compliance.
However, computer security experts like Berkeley's senior researcher, Dr. Nicholas Weaver, have been warning that these &#8220;backdoors&#8221; pose significant security risks for years, <a href="https://reason.com/2024/10/11/chinese-hackers-used-u-s-government-mandated-wiretap-systems/">per</a> Reason's report. 
Other cybersecurity experts say the Salt Typhoon intrusion exposes the inherent dangers of backdoor access.
&#8220;The problem with backdoors is well-known,&#8221; said Matthew Green, a cryptography professor at Johns Hopkins University. &#8220;Any channel devoted to one party will eventually be discovered and abused by another.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41297880/california-judge-rules-gov-newsoms-hemp-ban-stands-despite-industry-pushback"> California Judge Rules Gov. Newsom&#8217;s Hemp Ban Stands Despite Industry Pushback</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

LUMN

Lawmakers Demand Answers From AT&T, Verizon, And Lumen Over Chinese Hack

Camden Property Trust Reports Minor Damage From Hurricanes Helene And Milton, Will Provide Updates If Material Changes Occur

UMH Properties Reports Minimal Impact From Hurricane Milton, No Material Effect On Operations Or Financial Results

Insider Trades

ALVR

Octagon Capital Advisors Reports 9.7% Passive Stake In AlloVir

Looking into the current session, Permian Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) shares are trading at $14.52, after a 0.83% spike. Moreover, over the past month, the stock spiked by 7.64%, but in the past year, fell by 3.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1728677757_0.png" alt="Past Year Chart" />

<h3>Comparing Permian Resources P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Permian Resources has a lower P/E than the aggregate P/E of 18.07 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728677757_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Permian Resources

The S&amp;P 500 and Dow Jones Industrial Average <a href="https://www.benzinga.com/news/earnings/24/10/41293799/s-p-500-dow-jones-hit-new-record-highs-as-financial-stocks-soar-on-upbeat-earnings">both achieved record highs</a> this week.
A strong kickoff to the third-quarter earnings season fueled both indexes, offsetting concerns from last <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41270761/september-inflation-hotter-than-expected-jobless-claims-spike-the-most-in-over-a-">month's unexpected inflation surge.</a>
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) all exceeded analyst earnings forecasts Friday. This triggered a stock rally and propelled the financial <a href="https://www.benzinga.com/news/earnings/24/10/41293190/us-banks-top-q3-earnings-estimates-jpmorgan-delivers-robust-beat-financial-sector-stocks-hit-record">sector to new highs.</a>
In contrast, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) faced investor disappointment. The Austin, Texas-based car company is one of the worst performers within the S&amp;P 500 this week.
The much-anticipated "We, Robot" event on Thursday was partly to blame. The presentation failed to impress analysts and investors, alike. Critics said it was <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41295072/tesla-robotaxi-day-event-more-fanfare-than-substance-8-analysts-on-cybercab-optimus">more fanfare than substance</a>. 
While the company showcased its CyberCab and Optimus robot, key details about commercialization and timelines were lacking. The event sparked mixed reactions from investors, with concerns about whether Tesla can deliver on its ambitious autonomous vehicle promises.
As a result, the Elon Musk-led EV manufacturer saw its <a href="https://www.benzinga.com/markets/equities/24/10/41289653/tesla-stock-poised-to-pullback-to-1-month-low-whats-going-on">share price plunge Friday</a>. 
You might have missed…
<h3 class="wp-block-heading">Economic data disappoints</h3>
September inflation reports for both <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41270761/september-inflation-hotter-than-expected-jobless-claims-spike-the-most-in-over-a-">consumers</a> and <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41290382/producer-inflation-rises-more-than-expected-in-september-as-food-transportation-c">producers</a> come in higher than expected, while jobless claims posted the sharpest rise in over a year.
Despite the inflation uptick, interest rate expectations remained largely unchanged, with most traders and economists maintaining their outlook for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">a November rate cut</a>. The unemployment spike was attributed to temporary factors, including Michigan auto layoffs and Hurricane Helene.
<h3 class="wp-block-heading">No Stimulus Measures In China</h3>
Chinese stocks saw their worst weekly performance of the year. The absence of expected stimulus measures from Chinese authorities weighed heavily on investor sentiment, despite a strong rally in recent weeks.
<h3 class="wp-block-heading">Mortgage Rates Surge</h3>
Mortgage rates saw a sharp reversal last week, jumping to 6.36% and leading to a 5.1% drop in homebuyer applications. The housing market awaits further rate cuts, but rising Treasury yields —driven by a resilient labor market — pose significant challenges to mortgage rate relief <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41249628/mortgage-rates-make-dramatic-u-turn-freezing-homebuyers-applications-fall-5-as-ma">in the near term.</a>
<h3 class="wp-block-heading">Google fights back</h3>
Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google is challenging the Department of Justice&#8217;s efforts to break up its search dominance, labeling the proposed <a href="https://www.benzinga.com/markets/equities/24/10/41244481/google-cries-foul-as-doj-moves-to-break-up-search-giant-calls-recommendations-radical-as-antitru">antitrust remedies as radical.</a> 
The tech giant argues the DOJ's recommendations could dismantle its core business, impacting innovation and consumer choice.
Keep Reading:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41281645/18-stocks-to-buy-7-to-sell-this-earnings-season-goldman-sachs-calls-it-the-year-of-">18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It &#8216;The Year Of The Stock Picker&#8217;</a></li>
</ul>

Earnings

Equities

Econ #s

Economics

GOOGL

TSLA

Wall Street Marks New Record Highs On Strong Start To Earnings Season, Investors Downplay Inflation Surge, Tesla Disappoints: This Week In The Market

MAPS

WM Technology Got Notice Of Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq

Financing

AMCX

Millennium Management Reports 5.7% Passive Stake In AMC Networks

At September 30, 2024, Peabody has completed approximately $250 million of the anticipated $489 million of initial development capital to achieve longwall production in March 2026. With a $210 per metric ton benchmark price assumption, Centurion has an estimated net present value of $1.6 billion and a 25 percent internal rate of return.
"Peabody is committed to increasing shareholder value through a balanced approach of maximizing shareholder returns and developing Centurion," Mark Spurbeck, Peabody's Chief Financial Officer, said. "Centurion provides increased optionality to tightening metallurgical coal markets and will be a strategic asset in Peabody's global coal portfolio for decades."

Peabody Provides Update On Centurion Metallurgical Coal Mine Development; Integrated Mine Plan Complete With Estimated Net Present Value Of $1.6B; Average Annual Production Of 4.7M Tons At First Quartile Cost And Mine Life Of 25+ Years

Perspective gets FDA fast track status for radiopharmaceutical VMT01

Perspective draws buy at Truist on radiopharma potential

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Perspective Therapeutics (CATX – Research Rep...

Buy Rating Affirmed on Perspective Therapeutics Amid Promising VMT-α-NET Developments

LifeSci Capital analyst Anshul Dhankher has maintained their bullish stance on CATX stock, giving a Buy rating yesterday. Anshul Dhankher has given...

Buy Rating on Perspective Therapeutics Backed by Promising VMT-alpha-NET Clinical Results

Perspective Therapeutics a new buy at Wedbush on radiopharmaceutical assets

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oppenheimer analyst Jeff Jones maintained a Buy rating on Perspective Therapeutics (CATX – Research Report) today and set a price target of $22.00....

Oppenheimer Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

Perspective falls after data for radiopharmaceutical in skin cancer

Perspective Therapeutics (CATX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Anshul Dhan...

Maintained Buy Rating on CATX Amid Adjusted Success Probabilities and Clinical Hurdles

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), with a pri...

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment

ATNM

BAYRY

BMYMP

CATX

CLRB

GEHC

LNTH

NVSEF

TLPPF

Press Releases

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Comments

Perspective Therapeutics

Intérêt court

Perspective Therapeutics (AMEX:CATX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL